Intercept's OCA Data Bolster NASH Efficacy, But Pruritus Worries Worsen
Analysts call Intercept sell-off overblown in wake of EASL presentation of fuller Phase III data for OCA in NASH. But while depth is added to efficacy argument, pruritus concerns possibly worsen.
You may also be interested in...
Executives and analysts predict trends spanning M&A, leadership diversity, curative gene therapy commercialization, biosimilars strategy and more. Expect technology innovation to continue to drive investment and deal making in biopharma.
Other NASH registration trails have targeted fibrosis, but Galectin's mostly-resolved discussions with US FDA will allow the belapectin program to focus of signs and symptoms of the disease.
Galectin faces a dual challenge - do its planned trial well and trust that the study design will lead the galectin-3 inhibitor belapectin to a niche position in NASH.